BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24718851)

  • 1. Cost-effectiveness of pneumococcal vaccines for adults in the United States.
    Chen J; O'Brien MA; Yang HK; Grabenstein JD; Dasbach EJ
    Adv Ther; 2014 Apr; 31(4):392-409. PubMed ID: 24718851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine.
    Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK
    JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.
    Choi MJ; Kang SO; Oh JJ; Park SB; Kim MJ; Cheong HJ
    Hum Vaccin Immunother; 2018; 14(8):1914-1922. PubMed ID: 29953307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program.
    Stoecker C; Kobayashi M; Matanock A; Cho BH; Pilishvili T
    Vaccine; 2020 Feb; 38(7):1770-1777. PubMed ID: 31889609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental Cost-Effectiveness of 13-valent Pneumococcal Conjugate Vaccine for Adults Age 50 Years and Older in the United States.
    Stoecker C; Kim L; Gierke R; Pilishvili T
    J Gen Intern Med; 2016 Aug; 31(8):901-8. PubMed ID: 26976292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine.
    Gouveia M; Jesus G; Inês M; Costa J; Borges M
    Hum Vaccin Immunother; 2019; 15(4):850-858. PubMed ID: 30633615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults.
    Rey-Ares L; Averin A; Mac Mullen M; Hariharan D; Atwood M; Carballo C; Huang L
    Infect Dis Ther; 2024 Jun; 13(6):1235-1251. PubMed ID: 38700655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults.
    Smith KJ; Nowalk MP; Raymund M; Zimmerman RK
    Vaccine; 2013 Aug; 31(37):3950-6. PubMed ID: 23806240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older.
    Jackson LA; Gurtman A; van Cleeff M; Frenck RW; Treanor J; Jansen KU; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3594-602. PubMed ID: 23688525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study.
    Guo J; Zhang H; Zhang H; Lai X; Wang J; Feng H; Fang H
    Vaccine; 2023 Jan; 41(3):716-723. PubMed ID: 36522264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the cost-effectiveness of a sequential pneumococcal vaccination compared to single-dose vaccination strategy for adults in Hong Kong.
    Shami JJP; Pathadka S; Chan EW; Hui J; Sato R; Patil S; Li X
    Hum Vaccin Immunother; 2020 Aug; 16(8):1937-1944. PubMed ID: 31977268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany.
    Kuchenbecker U; Chase D; Reichert A; Schiffner-Rohe J; Atwood M
    PLoS One; 2018; 13(5):e0197905. PubMed ID: 29795647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older Populations.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    J Am Geriatr Soc; 2020 Jun; 68(6):1271-1278. PubMed ID: 32086950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysis.
    Wateska AR; Nowalk MP; Lin CJ; Harrison LH; Schaffner W; Zimmerman RK; Smith KJ
    Hum Vaccin Immunother; 2019; 15(4):863-872. PubMed ID: 30633706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia.
    Chen C; Beutels P; Wood J; Menzies R; MacIntyre CR; McIntyre P; Newall AT
    Vaccine; 2018 Oct; 36(42):6307-6313. PubMed ID: 30213457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices.
    Matanock A; Lee G; Gierke R; Kobayashi M; Leidner A; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(46):1069-1075. PubMed ID: 31751323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults.
    Feldman C; Dlamini SK; Madhi SA; Meiring S; von Gottberg A; de Beer JC; de Necker M; Stander MP
    PLoS One; 2020; 15(1):e0227945. PubMed ID: 31995597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.